Drug Trial Radar · NCT07870330
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Dec 7, 2027
Study completion Dec 7, 2027
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to \<18 years of age).
Conditions
- Seasonal Influenza
Interventions
mRNA-1010Biological
Suspension for injection
Fluarix TrivalentBiological
Suspension for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Time frame: Up to Day 7 (7 days after vaccination)
- Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 28 (28 days after vaccination)
- Number of Participants with AEs Leading to Discontinuation, Serious Adverse Events (SAEs), or Adverse Events of Special Interest (AESI)Time frame: Day 1 through Day 365
- Number of Participants with Medically Attended AEs (MAAEs)Time frame: Day 1 through Day 181
- Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) AssayTime frame: Day 29
- Percentage of Participants Reaching Seroconversion, as Measured by HAI AssayTime frame: Day 29
- Percentage of Participants With HAI Titer ≥ 1:40 at Day 29Time frame: Day 29
- Geometric Mean Fold Rise (GMFR) of Anti-HA antibodies, as Measured by HAI AssaysTime frame: Day 29
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Paradigm Clinical Research Centers, LLC
Modesto, California · Recruiting
Paradigm Clinical Research Centers, LLC
Aurora, Colorado · Recruiting
Clinical Research Institute, Inc
Minneapolis, Minnesota · Recruiting
Senders Pediatrics
South Euclid, Ohio · Recruiting
West Houston Clinical Research Service
Houston, Texas · Recruiting
Clinical Research Partners, LLC.
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.